Table 1.
Proportion of patients with each of the specified risk factors at baseline from RCT
| RA N = 3770, PYR = 14,744 |
AD N = 2636, PYR = 4628 |
AA N = 1303, PYR = 1868 |
|
|---|---|---|---|
| ASCVD | 119 (3.2) | 25 (0.9) | 12 (0.9) |
| Current smoker | 603 (16.0) | 634 (24.1) | 222 (17.0) |
| Hypertension | 1348 (35.8) | 349 (13.2) | 145 (11.1) |
| HDL < 40 mg/dL | 308 (8.2) | 360 (13.7) | 116 (8.9) |
| Diabetes mellitus | 335 (8.9) | 71 (2.7) | 40 (3.1) |
| ≥ 65 yearsa | 632 (16.8) | 101 (3.8) | 6 (0.5) |
| BMI ≥ 30 kg/m2 | 1100 (29.2) | 496 (18.8) | 266 (20.4) |
| History of malignancy | 52 (1.4) | 27 (1.0) | 17 (1.3) |
| Severe mobility impairment (EQ-5D)b | 468 (12.4) | 51 (1.9) | 4 (0.3) |
| Any of 9 risk factorsc | 2619 (69.5) | 1373 (52.1) | 659 (50.6) |
Data are n (%)
AA alopecia areata; AD atopic dermatitis; ASCVD atherosclerotic cardiovascular disease; BMI body mass index; CV cardiovascular; EQ-5D EuroQol-5 dimension; HDL high-density lipoprotein; MACE major adverse cerebrocardiovascular event; MI myocardial infarction; N number of patients in analysis population; n number of patients in the specified category; PYR patient-years of exposure for risk; RA rheumatoid arthritis
aThe age of participants in AA clinical trials was limited to 60 years or younger for males and 70 years or younger for females to reduce concomitant androgenic alopecia
bSevere mobility impairment indicated by a response of either ‘I have severe problems in walking about’ or ‘I am unable to walk about’
cASCVD, current or past smoking (past smoking was not systematically documented in all trials), hypertension, HDL cholesterol < 40 mg/dL, diabetes mellitus, age 65 years or older, BMI 30 kg/m2, history of malignancy, and severe mobility impairment at EQ-5D baseline